Stock AnalizGuardian Pharmacy Services, Inc. GRDN
Retail-Drug Stores and Proprietary Stores · IPO 2024 · data as of November 13, 2026
Guardian Pharmacy Services, Inc. (GRDN) is a consumer staples company listed in the US with a market value of about $3.1B. In the twelve months to September 30, 2026 it had revenue of $1.5B and net income of $75M, a net margin of 5.1%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 42.2, a price to free cash flow of 32.6, a 5-year average ROIC of -4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 62% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | $1.5B | $1.4B | $1.2B |
| Net income | $75M | $49M | -$110M |
| Free cash flow | $96M | $87M | $43M |
| EPS (diluted) | $1.17 | $0.78 | — |
| Net margin | 5.1% | 3.4% | -9.0% |
| ROIC | — | 19.0% | -27.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $50.14, 1% above the current price; targets range from $47.00 to $52.00; the consensus rating is “Strong buy”; expected EPS is $1.30 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Guardian Pharmacy Services’s P/E ratio?
About 42.2, based on the last twelve months of diluted earnings per share (forward P/E about 34.8).
Is Guardian Pharmacy Services stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 62% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Guardian Pharmacy Services pay a dividend?
Not currently.
Is Guardian Pharmacy Services a good stock to buy?
We do not give buy or sell advice. Guardian Pharmacy Services scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.